IGF2BP3 and eosinophilia-myalgia syndrome: In conclusion, our research findings provided insights into the involvement of the IGF2BP3/UCA1/c-MYC/GLS1 signaling axis in the regulation of glutamine metabolism, highlighting its potential as a therapeutic approach for EMs.